---
document_datetime: 2023-09-21 19:43:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/aflunov-epar-all-authorised-presentations_en.pdf
document_name: aflunov-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8039917
conversion_datetime: 2025-12-19 03:48:11.690637
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size              |
|------------------|-------------------|------------|--------------------------|---------------------------|----------------------------|---------------------------|------------------------|
| EU/1/10/658/001  | AFLUNOV           | -- 1       | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 1 pre-filled syringe   |
| EU/1/10/658/002  | AFLUNOV           | -- 1       | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 10 pre-filled syringes |

--1   Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: A/turkey/Turkey/1/2005 (H5N1) - like strain (NIBRG-23) (clade 2.2.1) 7.5 micrograms** per 0.5 ml dose

* propagated in fertilised hens' eggs from healthy chicken flocks

** expressed in microgram haemagglutinin.

Adjuvant MF59C.1 containing:

squalene

9.75 milligrams

polysorbate 80

1.175 milligrams

sorbitan trioleate

1.175 milligrams